Quantumzyme Corp. Proposes Name Change to Quantum Genesis AI Corp. to Reflect AI Integration in Enzyme Engineering

Quantumzyme Corp., a biotransformation company developing enzyme-based pharmaceutical manufacturing solutions, announced its Board of Directors has approved a proposed corporate name change to Quantum Genesis AI Corp. The change, which requires approval from the Financial Industry Regulatory Authority (FINRA), aims to align the company's identity with its expanding use of artificial intelligence in enzyme engineering initiatives. CEO Naveen Kulkarni stated the proposed rebranding represents the direction of the company's research and development efforts. "This prospective evolution aligns with our continued work toward combining intelligence-driven computational tools with sustainable chemistry to support our long-term strategy," Kulkarni said.

The company's technology framework integrates quantum mechanics, molecular modeling, machine learning, and computational design principles to develop biocatalysts for more sustainable pharmaceutical manufacturing. Quantumzyme has been advancing its enzyme engineering through laboratory-scale samples of enzymatic ibuprofen prepared for external evaluation and peer-reviewed research published in RSC Sustainability. The company is exploring how its framework may contribute to environmental improvements by supporting reduction of chemical waste, minimizing solvent use, and lowering carbon intensity associated with traditional synthesis processes. While further validation and scale-up are required, Quantumzyme intends to demonstrate how its sustainability-focused approach may offer economic and environmental advantages relative to conventional chemical manufacturing.

The company is assessing opportunities for partnerships, technology licensing, and collaborative development programs that may provide pathways for revenue through licensing arrangements or joint development structures. These opportunities remain subject to continued technological progress, market conditions, and successful external validation. Quantumzyme believes its strategic initiatives, combined with the prospective name change, may enhance its visibility within markets focused on AI-driven innovation, sustainable chemistry, and domestic pharmaceutical manufacturing resilience. "Our objective is to position the Company for future opportunities by aligning our technological evolution with a corporate identity that reflects our growth strategy," Kulkarni added.

The company anticipates that its combination of AI-enabled modeling, enzyme engineering capabilities, and sustainability-focused development priorities may support long-term expansion into multiple Active Pharmaceutical Ingredient categories. Quantumzyme will proceed with submitting the required corporate action request to FINRA, which must review and approve the proposed name change and any associated ticker symbol updates before they take effect. For more information, please visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.